Replies to post #129 on Cell Genesys, Inc. (CEGE)

[florida135]

S&P MAINTAINS HOLD RECOMMENDATION ON SHARES OF CELL GENESYSFont size: A | A | Aundefined undefined | S&P Marketscope
RELATED QUOTES


12:17 PM ET 9/11/08
Symbol Last % Chg
CEGE 0.75 4.15%
Real time quote.

SNPMarketScopeResearchNotes2008-09-11 11:22:56.000CEGECELL GENESYSJ.Englander-CFAS&P MAINTAINS HOLD RECOMMENDATION ON SHARES OF CELL GENESYSCEGE says the FDA has placed a partial clinical hold on its GVAX phase III program for prostate cancer, based on higher number of deaths for those on therapy in Vital II trial on GVAX plus Taxotere in symptomatic prostate cancer patients. We note that the FDA is allowing ongoing maintenance treatment with GVAX alone for those in Vital I trial on asymptomatic prostate cancer patients, pending patient notification of adverse events in Vital II trial. We view this as positive news, given that FDA could have halted maintenance dosing. We keep $2.50 risk-adjusted NPV target price.|US;CEGE|3774|72664